Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2019.11.012
Abstract: INTRODUCTION Ipilimumab plus nivolumab has been approved for intermediate- and poor-risk metastatic renal cell carcinoma (RCC). However, the activity in non-clear cell RCC (nccRCC) is unknown. PATIENTS AND METHODS Patients from Cleveland Clinic and the… read more here.
Keywords: non clear; plus nivolumab; renal cell; ipilimumab plus ... See more keywords
Activity of regorafenib plus nivolumab
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-020-0389-8
Abstract: The multikinase inhibitor regorafenib has shown immunomodulatory activity when combined with immunecheckpoint inhibition (ICI) in mouse models of colorectal cancer (CRC); in humans, this synergistic activity could help to overcome lack of response to ICI.… read more here.
Keywords: plus nivolumab; gastric cancer; crc; cancer ... See more keywords
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
Sign Up to like & getrecommendations! Published in 2020 at "Nature medicine"
DOI: 10.1038/s41591-020-1085-z
Abstract: Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies has shown remarkable pathological responses in melanoma1 and colorectal cancer2. In NABUCCO (ClinicalTrials.gov: NCT03387761), a single-arm feasibility trial, 24 patients with stage III urothelial cancer (UC) received two… read more here.
Keywords: plus nivolumab; urothelial cancer; trial; locoregionally advanced ... See more keywords
Severe necrotizing myopathy after COVID‐19 vaccine with BNT162b2 and regimen with ipilimumab plus nivolumab in a patient with advanced melanoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.17760
Abstract: Immune checkpoint inhibitors (ICIs) have dramatically changed the prognosis of advanced melanoma patients, but also exposed them to immune-related adverse events (irAEs).1 Furthermore, with the combination ipilimumab (IPI) plus nivolumab (NIVO) some rare irAEs, such… read more here.
Keywords: advanced melanoma; covid; plus nivolumab; severe necrotizing ... See more keywords
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3726
Abstract: Abstract Purpose: This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI). Patients and Methods: A phase I expansion cohort… read more here.
Keywords: metastatic urothelial; phase expansion; cabozantinib plus; urothelial carcinoma ... See more keywords
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5037
Abstract: 5037Background: Previous treatment with ICI is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for mUC. There is lack of data regarding the u... read more here.
Keywords: cabozantinib plus; plus nivolumab; nivolumab cabonivo; study cabozantinib ... See more keywords
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4503
Abstract: 4503 Background: Transurethral resection of bladder tumor (TURBT) plus systemic therapy has been known for decades to achieve durable bladder-intact survival in a subset of patients with MIBC but efforts to advance this paradigm have… read more here.
Keywords: cisplatin plus; cytology; bladder; ccr ... See more keywords
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.01944
Abstract: PURPOSE To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non–clear-cell renal cell carcinoma (RCC). PATIENTS AND METHODS Patients had advanced non–clear-cell renal carcinoma who underwent… read more here.
Keywords: cell; non clear; cabozantinib; cohort ... See more keywords
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14051162
Abstract: Simple Summary Despite recent progress on the treatment of metastatic uveal melanoma (mUM), prognosis remains dismal for the majority of patients. Directed liver therapies including selective internal radiation therapy (SIRT) have been the pillar of… read more here.
Keywords: uveal melanoma; sirt; plus nivolumab; ipilimumab plus ... See more keywords